Almirall S.A. Cash Flow Conversion Efficiency
Almirall S.A. cash flow conversion efficiency. Based on the latest financial reports, Almirall S.A. (ALM) has a cash flow conversion efficiency ratio of 0.060x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€88.75 Million ≈ $103.76 Million USD) by net assets (€1.48 Billion ≈ $1.72 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Almirall S.A. (2005–2024)
Cash flow conversion efficiency of Almirall S.A. from 2005 to 2024. This chart illustrates how Almirall S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Almirall S.A. stock quote for real-time trading data and today's change.
Almirall S.A. Cash Flow Conversion Ratio Explained
Almirall S.A. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Almirall S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Almirall S.A. ranked by their cash flow conversion efficiency. Also see Almirall S.A. (ALM) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Henan Mingtai Al.Industrial Co Ltd
SHG:601677
|
-0.013x |
|
HMS Networks AB (publ)
ST:HMS
|
0.067x |
|
SIMMTECH Co. Ltd
KQ:222800
|
-0.092x |
|
Zhuzhou Smelter Group Co Ltd
SHG:600961
|
0.076x |
|
Shanghai Bairun Flavor & Fragrance Co Ltd
SHE:002568
|
0.054x |
|
Clicks
JSE:CLS
|
0.172x |
|
AstraZeneca PLC
LSE:AZN
|
0.057x |
|
Cal-Comp Electronics (Thailand) Public Company Limited
TW:9105
|
0.096x |
Annual Cash Flow Conversion Efficiency for Almirall S.A. (2005–2024)
The table below shows the annual cash flow conversion efficiency of Almirall S.A. from 2005 to 2024. Review ALM free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €1.49 Billion ≈ $1.74 Billion |
€160.77 Million ≈ $187.95 Million |
0.108x | +69.08% |
| 2023-12-31 | €1.46 Billion ≈ $1.71 Billion |
€93.48 Million ≈ $109.29 Million |
0.064x | -45.69% |
| 2022-12-31 | €1.32 Billion ≈ $1.54 Billion |
€155.10 Million ≈ $181.33 Million |
0.118x | -35.32% |
| 2021-12-31 | €1.29 Billion ≈ $1.50 Billion |
€233.85 Million ≈ $273.40 Million |
0.182x | +43.80% |
| 2020-12-31 | €1.30 Billion ≈ $1.52 Billion |
€164.76 Million ≈ $192.63 Million |
0.126x | -41.38% |
| 2019-12-31 | €1.28 Billion ≈ $1.50 Billion |
€276.15 Million ≈ $322.84 Million |
0.216x | +79.51% |
| 2018-12-31 | €1.19 Billion ≈ $1.39 Billion |
€143.21 Million ≈ $167.43 Million |
0.120x | +2135.49% |
| 2017-12-31 | €1.13 Billion ≈ $1.33 Billion |
€6.09 Million ≈ $7.12 Million |
0.005x | -92.22% |
| 2016-12-31 | €1.52 Billion ≈ $1.78 Billion |
€105.06 Million ≈ $122.82 Million |
0.069x | -40.86% |
| 2015-12-31 | €1.46 Billion ≈ $1.71 Billion |
€170.88 Million ≈ $199.78 Million |
0.117x | -75.81% |
| 2014-12-31 | €1.34 Billion ≈ $1.57 Billion |
€646.93 Million ≈ $756.34 Million |
0.483x | +539.23% |
| 2013-12-31 | €888.33 Million ≈ $1.04 Billion |
€67.11 Million ≈ $78.46 Million |
0.076x | -38.11% |
| 2012-12-31 | €923.67 Million ≈ $1.08 Billion |
€112.75 Million ≈ $131.82 Million |
0.122x | +4.19% |
| 2011-12-31 | €854.71 Million ≈ $999.25 Million |
€100.14 Million ≈ $117.07 Million |
0.117x | -45.02% |
| 2010-12-31 | €819.30 Million ≈ $957.85 Million |
€174.60 Million ≈ $204.13 Million |
0.213x | -38.82% |
| 2009-12-31 | €751.00 Million ≈ $878.00 Million |
€261.60 Million ≈ $305.84 Million |
0.348x | -- |
| 2008-12-31 | €0.00 ≈ $0.00 |
€233.10 Million ≈ $272.52 Million |
x | -- |
| 2007-12-31 | €573.65 Million ≈ $670.66 Million |
€179.03 Million ≈ $209.31 Million |
0.312x | +45.16% |
| 2006-12-31 | €763.21 Million ≈ $892.28 Million |
€164.09 Million ≈ $191.84 Million |
0.215x | +36.46% |
| 2005-12-31 | €898.52 Million ≈ $1.05 Billion |
€141.57 Million ≈ $165.51 Million |
0.158x | -- |
About Almirall S.A.
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfecti… Read more